Clinical Implementation of Preemptive Pharmacogenomics Testing for Personalized Medicine at an Academic Medical Center

Overview

Journal J Am Med Inform Assoc

Publisher Oxford University Press

Specialty Medical Informatics

Date 2024 Dec 12

PMID 39665424

Authors

Bani Tamraz

Jaekyu Shin

Raman Khanna

Jessica Van Ziffle

Susan Knowles

Susan Stregowski

Eunice Wan

Rajesh Kamath

Christopher Collins

Choeying Phunsur

Benjamin Tsai

Patsy Kong

Clari Calanoc

Aleta Pollard

Rajeev Sawhney

Jennifer Pleiman

Walter Patrick Devine

Rhiannon Croci

Aparna Sashikanth

Lisa Kroon

Russell Cucina

Aleks Rajkovic

Affiliations

Soon will be listed here.

Abstract

Objective: This article describes the implementation of preemptive clinical pharmacogenomics (PGx) testing linked to an automated clinical decision support (CDS) system delivering actionable PGx information to clinicians at the point of care at UCSF Health, a large Academic Medical Center.

Methods: A multidisciplinary team developed the strategic vision for the PGx program. Drug-gene interactions of interest were compiled, and actionable alleles identified. A genotyping platform was selected and validated in-house. Following HIPAA protocols, genotype results were electronically transferred and stored in electronic health records (EHRs). CDS was developed and integrated with electronic prescribing.

Results: We developed a customized PGx program for 56 medications and 15 genes. Two hundred thirty-three pharmacogenomic prescribing alerts and 15 pharmacogenomic testing prompts, approved by clinicians, were built into EHR to deliver actionable clinical PGx information to clinicians.

Conclusions: Our multidisciplinary team successfully implemented preemptive PGx testing linked to point-of-care CDS to guide clinicians with precise medication decision-making.

References

ODonnell P, Danahey K, Jacobs M, Wadhwa N, Yuen S, Bush A . Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014; 166C(1):68-75. PMC: 4000170. DOI: 10.1002/ajmg.c.31385. View

Cohen J . Overcoming regulatory and economic challenges facing pharmacogenomics. N Biotechnol. 2012; 29(6):751-6. DOI: 10.1016/j.nbt.2012.02.001. View

Hoffman J, Haidar C, Wilkinson M, Crews K, Baker D, Kornegay N . PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014; 166C(1):45-55. PMC: 4056586. DOI: 10.1002/ajmg.c.31391. View

Rinke M, Mikat-Stevens N, Saul R, Driscoll A, Healy J, Tarini B . Genetic services and attitudes in primary care pediatrics. Am J Med Genet A. 2013; 164A(2):449-55. DOI: 10.1002/ajmg.a.36339. View

Lazarou J, Pomeranz B, Corey P . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279(15):1200-5. DOI: 10.1001/jama.279.15.1200. View

Weitzel K, Elsey A, Langaee T, Burkley B, Nessl D, Obeng A . Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014; 166C(1):56-67. PMC: 4076109. DOI: 10.1002/ajmg.c.31390. View

Shuldiner A, Relling M, Peterson J, Hicks J, Freimuth R, Sadee W . The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013; 94(2):207-10. PMC: 3720847. DOI: 10.1038/clpt.2013.59. View

Swen J, van der Wouden C, Manson L, Abdullah-Koolmees H, Blagec K, Blagus T . A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023; 401(10374):347-356. DOI: 10.1016/S0140-6736(22)01841-4. View

Phillips K, Veenstra D, Oren E, Lee J, Sadee W . Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286(18):2270-9. DOI: 10.1001/jama.286.18.2270. View

10.

Klein T, Chang J, Cho M, Easton K, Fergerson R, Hewett M . Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 2002; 1(3):167-70. DOI: 10.1038/sj.tpj.6500035. View

11.

Bielinski S, Olson J, Pathak J, Weinshilboum R, Wang L, Lyke K . Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014; 89(1):25-33. PMC: 3932754. DOI: 10.1016/j.mayocp.2013.10.021. View

12.

Selkirk C, Weissman S, Anderson A, Hulick P . Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013; 17(3):219-25. DOI: 10.1089/gtmb.2012.0165. View

13.

McInnes G, Lavertu A, Sangkuhl K, Klein T, Whirl-Carrillo M, Altman R . Pharmacogenetics at Scale: An Analysis of the UK Biobank. Clin Pharmacol Ther. 2020; 109(6):1528-1537. PMC: 8144239. DOI: 10.1002/cpt.2122. View

14.

Goldspiel B, Flegel W, DiPatrizio G, Sissung T, Adams S, Penzak S . Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc. 2013; 21(3):522-8. PMC: 3994859. DOI: 10.1136/amiajnl-2013-001873. View

15.

Relling M, Klein T . CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89(3):464-7. PMC: 3098762. DOI: 10.1038/clpt.2010.279. View

16.

Scott S . Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther. 2012; 93(1):33-5. PMC: 3576863. DOI: 10.1038/clpt.2012.196. View

17.

Pulley J, Denny J, Peterson J, Bernard G, Vnencak-Jones C, Ramirez A . Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012; 92(1):87-95. PMC: 3581305. DOI: 10.1038/clpt.2011.371. View